FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency By Ogkologos - February 18, 2026 191 0 Facebook Twitter Google+ Pinterest WhatsApp Patients should be tested for genetic variants of DPYD prior to initiating treatment Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR 27-Year-Old Thought She Was Injured Falling Off A Horse, But Then... May 13, 2019 Enhancements to NCI’s SEER Program Creating New Research Opportunities August 23, 2018 First-Line Pembrolizumab Continues to Show Durable Clinical Benefit After 5 Years... October 31, 2022 COVID-19 Vaccines May Be Less Effective in Some People with Cancer May 26, 2021 Load more HOT NEWS What’s happened to cancer clinical trials during the COVID-19 pandemic? Study Suggests Reviewing Lung Cancer Screening Criteria for African Americans Longer PFS in Patients with Advanced Melanoma Treated with TILs than... ¿Es seguro el CBD para las personas con cáncer?
